tbuckley/cabot-search huggingface dataset:
Metastatic Breast Cancer Collateral Damage (MBCCD) project: Think tank of advocates and provider-survivors.
Authors: Leah Eshraghi, Heather Cooper Ortner, Jessica Noelle Clague DeHart, Annette Stanton, Timothy Williamson, Alexandra Jorge, Nwamaka Obidegwu, Susan M. Love
Journal: Journal of Clinical Oncology (2017)

55 Background: From The Health of Women (HOW) Study, we found that participants living with metastatic breast cancer (MBC) had a considerably diminished quality of life (QoL) compared to those with less advanced breast cancer. When faced with MBC, managing and minimizing collateral damage (CD) resulting from sequential and often continuous treatments is crucial to improving QoL. The aim of the MBCCD Project was to characterize the unique experience of MBC to identify and address potential areas of need in this underserved population. Methods: Findings from the MBCCD survey (515 MBC respondents) were presented and discussed at a two-day in-person Think Tank with our Advocate Task Force–10 women and men living with MBC–and 28 provider-survivors. Provider-survivors—consisting of healthcare providers who also had been treated for cancer—represented the full spectrum of providers that MBC patients may need, including nurses, oncologists, and surgeons, to physical therapists, psychologists, social workers, palliative care specialists, and faith leaders. The group was selected to address issues from both perspectives of care to ensure that recommendations would fully address patients’ needs and could be easily implemented in the current health care delivery system. Results: The Think Tank provided multiple opportunities to discuss the survey findings and develop recommendations on ways to educate providers about the needs of MBC patients and help alleviate the CD patients experience. A wide variety of unmet needs were discussed, including increased access to clinical trials, centralized resources for financial assistance, addressing sensitive or non-discussed issues, such as fertility and sexuality, and expanding awareness of palliative care programs. We are in the process of finalizing the recommendations and will disseminate widely to providers, MBC patients, and caregivers. Conclusions: Having a panel of people seated simultaneously on both sides of the cancer diagnosis and treatment conversation resulted in recommendations that did not shy away from addressing complex issues while simultaneously having a high probability for dissemination and implementation within the health care system.
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Authors: Tiara T. Byrd, Kristen Fousek, Antonella Pignata, Christopher Szot, Heba Samaha, Steven Seaman, Lacey Dobrolecki, Vita S. Salsman, Htoo Zarni Oo, Kevin Bielamowicz, Daniel Landi, Nino Rainusso, John Hicks, Suzanne Powell, Matthew L. Baker, Winfried S. Wels, Joachim Koch, Poul H. Sorensen, Benjamin Deneen, Matthew J. Ellis, Michael T. Lewis, Meenakshi Hegde, Bradley S. Fletcher, Brad St. Croix, Nabil Ahmed
Journal: Cancer Research (2017)

Abstract Triple-negative breast cancer (TNBC) is an aggressive disease lacking targeted therapy. In this study, we developed a CAR T cell–based immunotherapeutic strategy to target TEM8, a marker initially defined on endothelial cells in colon tumors that was discovered recently to be upregulated in TNBC. CAR T cells were developed that upon specific recognition of TEM8 secreted immunostimulatory cytokines and killed tumor endothelial cells as well as TEM8-positive TNBC cells. Notably, the TEM8 CAR T cells targeted breast cancer stem–like cells, offsetting the formation of mammospheres relative to nontransduced T cells. Adoptive transfer of TEM8 CAR T cells induced regression of established, localized patient-derived xenograft tumors, as well as lung metastatic TNBC cell line–derived xenograft tumors, by both killing TEM8+ TNBC tumor cells and targeting the tumor endothelium to block tumor neovascularization. Our findings offer a preclinical proof of concept for immunotherapeutic targeting of TEM8 as a strategy to treat TNBC. Significance: These findings offer a preclinical proof of concept for immunotherapeutic targeting of an endothelial antigen that is overexpressed in triple-negative breast cancer and the associated tumor vasculature. Cancer Res; 78(2); 489–500. ©2017 AACR.
Microscopic and macroscopic approaches to the mental representations of second languages
Authors: Zhenguang G. Cai, Haitao Liu
Journal: Behavioral and Brain Sciences (2017)

With a particular reference to second language (L2), we discuss (1) how structural priming can be used to tap into L2 representations and their relationships with first and target language representations; and (2) how complex networks additionally can be used to reveal the global and local patterning of L2 linguistic features and L2 developmental trajectories.
Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti–VEGF Drug Type for 1 Year in the IRIS Registry
Authors: Prethy Rao, Flora Lum, Kevin Wood, Craig Salman, Bhavya Burugapalli, Rebecca Hall, Sukhminder Singh, David W. Parke, George A. Williams
Journal: Ophthalmology (2017)
Serration pattern analysis for differentiating epidermolysis bullosa acquisita from other pemphigoid diseases
Authors: Joost M. Meijer, Ingeborg Atefi, Gilles F.H. Diercks, Artem Vorobyev, Janny Zuiderveen, Hillegonda J. Meijer, Hendri H. Pas, Detlef Zillikens, Enno Schmidt, Marcel F. Jonkman
Journal: Journal of the American Academy of Dermatology (2017)
Multicenter phase II study of cisplatin, pemetrexed, plus bevacizumab followed by maintenance pemetrexed plus bevacizumab for patients with advanced or recurrent non-squamous non-small cell lung cancer: MAP study
Authors: Y. Tsutani, Y. Miyata, T. Masuda, K. Fujitaka, M. Doi, Y. Awaya, S. Kuyama, S. Kitaguchi, K. Ueda, M. Okada
Journal: Annals of Oncology (2017)
Aumento do número de enterococos resistentes à vancomicina isolados em Helsínquia, Finlândia
Authors: J Vuopio-Varkila, J Suppola, N Klinger, E Tarkka, E Kolho
Journal: Eurosurveillance (1997)

O aparecimento de infeccoes hospitalares devidas a bacterias resistentes aos antimicrobianos, tais como os enterococos resistentes a vancomicina (ERV), tornou-se uma preocupacao universal. Nos hospitais dos Estados Unidos (EU), o ERV disseminou-se rapidamente e actualmente e responsavel por um decimo das infeccoes enterococicas adquiridas em hospital e notificadas para o Programa Nacional de Vigilância das Infeccoes Nosocomiais do CDC (Centers for Disease Control and Prevention) (1).
Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database
Authors: Sukhmani K. Padda, Xiaopan Yao, Alberto Antonicelli, Jonathan W. Riess, Yue Shang, Joseph B. Shrager, Robert Korst, Frank Detterbeck, James Huang, Bryan M. Burt, Heather A. Wakelee, Sunil S. Badve
Journal: Journal of Thoracic Oncology (2017)
ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary Syndrome)
Authors: Martin P. Than, John W. Pickering, Jeremy M. Dryden, Sally J. Lord, S. Andrew Aitken, Sally J. Aldous, Kate E. Allan, Michael W. Ardagh, John W.N. Bonning, Rosie Callender, Laura R.E. Chapman, Jonathan P. Christiansen, Andre P.J. Cromhout, Louise Cullen, Joanne M. Deely, Gerard P. Devlin, Katherine A. Ferrier, Christopher M. Florkowski, Christopher M.A. Frampton, Peter M. George, Gregory J. Hamilton, Allan S. Jaffe, Andrew J. Kerr, G. Luke Larkin, Richard M. Makower, Timothy J.E. Matthews, William A. Parsonage, W. Frank Peacock, Bradley F. Peckler, Niels C. van Pelt, Louise Poynton, A. Mark Richards, Anthony G. Scott, Mark B. Simmonds, David Smyth, Oliver P. Thomas, Andrew C.Y. To, Stephen A. Du Toit, Richard W. Troughton, Kim M. Yates
Journal: Circulation (2017)

Efforts to safely reduce length of stay for emergency department patients with symptoms suggestive of acute coronary syndrome (ACS) have had mixed success. Few system-wide efforts affecting multiple hospital emergency departments have ever been evaluated. We evaluated the effectiveness of a nationwide implementation of clinical pathways for potential ACS in disparate hospitals.This was a multicenter pragmatic stepped-wedge before-and-after trial in 7 New Zealand acute care hospitals with 31 332 patients investigated for suspected ACS with serial troponin measurements. The implementation was a clinical pathway for the assessment of patients with suspected ACS that included a clinical pathway document in paper or electronic format, structured risk stratification, specified time points for electrocardiographic and serial troponin testing within 3 hours of arrival, and directions for combining risk stratification and electrocardiographic and troponin testing in an accelerated diagnostic protocol. Implementation was monitored for >4 months and compared with usual care over the preceding 6 months. The main outcome measure was the odds of discharge within 6 hours of presentation RESULTS: There were 11 529 participants in the preimplementation phase (range, 284-3465) and 19 803 in the postimplementation phase (range, 395-5039). Overall, the mean 6-hour discharge rate increased from 8.3% (range, 2.7%-37.7%) to 18.4% (6.8%-43.8%). The odds of being discharged within 6 hours increased after clinical pathway implementation. The odds ratio was 2.4 (95% confidence interval, 2.3-2.6). In patients without ACS, the median length of hospital stays decreased by 2.9 hours (95% confidence interval, 2.4-3.4). For patients discharged within 6 hours, there was no change in 30-day major adverse cardiac event rates (0.52% versus 0.44%; P=0.96). In these patients, no adverse event occurred when clinical pathways were correctly followed.Implementation of clinical pathways for suspected ACS reduced the length of stay and increased the proportions of patients safely discharged within 6 hours.URL: https://www.anzctr.org.au/ (Australian and New Zealand Clinical Trials Registry). Unique identifier: ACTRN12617000381381.
P2.07-038 Thyroid Dysfunction Arising During KEYNOTE-001 Associated with Improved Efficacy of Pembrolizumab in NSCLC Patients at UCLA
Authors: A. Lisberg, K. Bornazyan, J. Madrigal, J. Bui, J. Carroll, C. Adame, J. Hunt, H. Lu, Z. Noor, A. Cummings, J.W. Goldman, E. Garon
Journal: Journal of Thoracic Oncology (2017)
Frequency of concomitant use of opioids and psychoactive medications among cancer patients referred to outpatient palliative care at a comprehensive cancer center.
Authors: Ahsan Azhar, Ali Haider, Angelique Wong, Maria Agustina Cerana, Madhuri Adabala, Vishidha Reddy Balankari, Diane D Liu, Seyedeh Dibaj, Janet L. Williams, Eduardo Bruera
Journal: Journal of Clinical Oncology (2017)

240 Background: There are potential severe effects when patients taking opioids receive other psychoactive medications. However, such combinations are sometimes necessary in palliative care. The purpose of this study was to determine the frequency of concomitant use of opioids + psychoactive medications in cancer patients referred to our outpatient palliative care center. Methods: Retrospective data obtained from consecutive consults was analyzed to determine the frequency of patients on opioids alone versus concomitant opioids + psychoactive medications at first presentation to our clinic. Association of type of medication with demographics and baseline characteristics was evaluated by Wilcoxon rank sum test for continuous variables and Chi-square (Fisher's exact) test for categorical variables. Results: Among 541 consecutive consult visits, 365 (67%) patients were taking opioids at the time of referral to our clinic: 209 (57%) were on opioids alone while 156 (43%) were on concomitant opioids + psychoactive medications [69 (44%) were on Opioid + Benzodiazepine, 46 (30%) were Opioid + Antidepressants, 41(26%) were on both). Patients in the concomitant groups were on higher Morphine Equivalent Daily Dose (MEDD, p = 0.007), had higher Edmonton Symptom Assessment Scores (ESAS) for pain (p = 0.017), anxiety (p &lt; 0.001), depression (p &lt; 0.001) and spiritual pain (p = 0.03). Conclusions: A large proportion (156, 43%) of cancer patients referred to outpatient palliative care was on concomitant opioids + psychoactive medications. These patients were on higher doses of opioids with higher levels of pain and psycho-social distress at the time of first presentation. Further studies are required to better understand the clinical implications of concomitant use of opioids + psychoactive medications in such patients.
PTH-032 Assessing the merits of sedation practice on comfort scores during gastroscopy training procedures in the uk
Authors: DJ Napier, ST Ward, J Brown, JT Anderson, P Dunckley
Journal: Gut (2017)

Introduction  Oesophagogastroduodenoscopy (OGD) is invaluable in the investigation and treatment of the upper gastrointestinal tract, but may cause patient anxiety and discomfort. Many patients elect to have no sedation. For the remainder, sedation practice varies with limited data regarding the merits or risks of differing sedation practice. The 2004 NCEPOD report “Scoping our practice” 1  raised concerns about sedation practice in the UK. Sedation practice is safer now 2 , but there has been limited research into minimising patient discomfort. This study compared patient comfort scores using different combinations of sedation; midazolam alone, a combination of pharyngeal anaesthesia (PA) and midazolam, or a combination of PA, midazolam and opiates.  Method  Retrospective data from the Joint Advisory Group (JAG) Endoscopy Training System (JETS) database of patients having OGDs performed by trainees between September 2009 and March 2016 was analysed. Procedures carried out under general anaesthesia and in patients under 18 years of age were excluded. Procedural discomfort was scored using the Gloucester comfort scale and grouped into: significant discomfort (4 or 5) and non-significant discomfort (1, 2 or 3). A multivariate analysis was used to compare data. Data was reviewed to determine if sedation practice effected immediate complication rates.  Results  826,593 OGDs were included in the study. 46.9% (387886) of procedures used PA alone, 23.4% (193014) PA and midazolam, 17.5% (144315) midazolam alone and 3.1% (26017) PA, midazolam and opiates. Average doses of midazolam used were 2.44 mg (PA and midazolam) compared with 2.68 mg (midazolam alone). Patients had less significant discomfort when midazolam was used in combination compared to midazolam alone; midazolam with PA (OR 0.69, 95% CI 0.67–0.72 p  Conclusion  This study describes a variation in sedation practice for OGDs in the UK. The use of midazolam in combination therapy is correlated with better comfort scores with no increase in immediate complications.  References  . Scoping our practice. NCEPOD. London 2004, (http://www.ncepod.org.uk/2004report/)  . Gavin DR, et al. The national colonoscopy audit: a nationwide assessment of the quality and safety of colonoscopy in the UK. Gut2013;62(2):242–249  Disclosure of Interest  None Declared
Vigilancia de la posible introducción de la variante sueca de Chlamydia trachomatis (swCT) en los Países Bajos
Authors: S A Morré, A Catsburg, I M de Boer, J Spaargaren, H Jc de Vries, J Schirm, P Hm Savelkoul, J van Steenbergen, C M Swaan
Journal: Eurosurveillance (2007)

En este informe se describen las actuaciones de los expertos de salud publica, en colaboracion con especialistas en enfermedades de transmision sexual (ETS), epidemiologos y microbiologos (moleculares), para investigar la posible introduccion de la variante swCT en los Paises Bajos
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
Authors: Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, Anthony C. Keech, Armando Lira Pineda, Estella Kanevsky, Julia Kuder, Sabina A. Murphy, J. Wouter Jukema, Basil S. Lewis, Lale Tokgozoglu, Ransi Somaratne, Peter S. Sever, Terje R. Pedersen, Marc S. Sabatine
Journal: Circulation (2017)

The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). We investigated the efficacy and safety of evolocumab in patients with peripheral artery disease (PAD) as well as the effect on major adverse limb events.FOURIER was a randomized trial of evolocumab versus placebo in 27 564 patients with atherosclerotic disease on statin therapy followed for a median of 2.2 years. Patients were identified as having PAD at baseline if they had intermittent claudication and an ankle brachial index of <0.85, or if they had a prior peripheral vascular procedure. The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina, or coronary revascularization. The key secondary end point was a composite of cardiovascular death, myocardial infarction, or stroke. An additional outcome of interest was major adverse limb events defined as acute limb ischemia, major amputation, or urgent peripheral revascularization for ischemia.Three thousand six hundred forty-two patients (13.2%) had PAD (1505 with no prior myocardial infarction or stroke). Evolocumab significantly reduced the primary end point consistently in patients with PAD (hazard ratio [HR] 0.79; 95% confidence interval [CI], 0.66-0.94; P=0.0098) and without PAD (HR 0.86; 95% CI, 0.80-0.93; P=0.0003; Pinteraction=0.40). For the key secondary end point, the HRs were 0.73 (0.59-0.91; P=0.0040) for those with PAD and 0.81 (0.73-0.90; P<0.0001) for those without PAD (Pinteraction=0.41). Because of their higher risk, patients with PAD had larger absolute risk reductions for the primary end point (3.5% with PAD, 1.6% without PAD) and the key secondary end point (3.5% with PAD, 1.4% without PAD). Evolocumab reduced the risk of major adverse limb events in all patients (HR, 0.58; 95% CI, 0.38-0.88; P=0.0093) with consistent effects in those with and without known PAD. There was a consistent relationship between lower achieved low-density lipoprotein cholesterol and lower risk of limb events (P=0.026 for the beta coefficient) that extended down to <10 mg/dL.Patients with PAD are at high risk of cardiovascular events, and PCSK9 inhibition with evolocumab significantly reduced that risk with large absolute risk reductions. Moreover, lowering of low-density lipoprotein cholesterol with evolocumab reduced the risk of major adverse limb events.URL: https://www.clinicaltrials.gov. Unique identifier: NCT01764633.
Hereditary cancer prevalence and communication about family history risks in palliative care.
Authors: A. Rab Razzak, Lauren Bailey, Brandon Yu, Mohammed Abusamaan, In Guk Kang, Brittany Ma, Bunmi Emidio, Oluwafemi Owodunni, Thomas J. Smith, Joann Bodurtha
Journal: Journal of Clinical Oncology (2017)

56 Background: Hereditary cancer (CA) assessment &amp; communication about family history (FH) risks in palliative care are underexplored &amp; could be critical for surviving relatives. FH may not be adequately reviewed &amp; appropriate information conveyed in the palliative care (PC) setting, even though family health is a legacy concern of patients. Cancer patients seeking PC never wish for their relatives to have CA &amp; may be an important resource for communication about their relative’s CA risk &amp; appropriate referrals. Methods: This prospective observational study among cancer patients receiving PC consultations was conducted at a 977-bed academic urban hospital between June 2016 &amp; March 2017. Data were collected through structured interviews and chart review during hospitalizations. Results: 75 adult cancer patients were enrolled. Patients’ average age at diagnosis was 55.3 ± 15.7 years. 41(55%) self-identified as male; 34(45%) as female; 20(27%) as black, 49 (65%) white, and 6(8%) other. 24 patients (32%) were considered to have pedigrees that merited referral as high-risk. 32 patients (43%) thought that their CA had a likely genetic or inherited component. 48(64%) thought the palliative care setting was an appropriate place to discuss the implications. The mean comfort level in addressing these questions was 8.7 on a 10 point scale with 10 indicating extremely comfortable. Conclusions: Review of FH may be an intervention that PC providers &amp; families can discuss &amp; incorporate in legacy activities. This could enhance CA prevention, especially among high-risk families. There is room for enhancement in how FH &amp; patient and family concern are integrated in the palliative &amp; cancer care continuum.
P2.06-040 WINNERS Study: Does a Formal Interactive Patient Education Program Positively Impact Patient Outcomes and Satisfaction after Thoracic Surgery
Authors: Melissa Culligan, Lindsey Black, Colleen Norton, Seantrese Wimbush, Christine Wells, Fatemeh Jorshari, Cindy Dove, Kendal Williams, Jamisson South, Lauren Tigini, Joseph Friedberg, Whitney Burrows, James Donahue, Shamus Carr
Journal: Journal of Thoracic Oncology (2017)
Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study
Authors: Maxwell M. Tran, Diana L. Lefebvre, Christoffer Dharma, David Dai, Wendy Y.W. Lou, Padmaja Subbarao, Allan B. Becker, Piush J. Mandhane, Stuart E. Turvey, Malcolm R. Sears, P. Subbarao, S.E. Turvey, S.S. Anand, M. Azad, A.B. Becker, A.D. Befus, M. Brauer, J.R. Brook, E. Chen, M. Cyr, D. Daley, S.D. Dell, J.A. Denburg, Q. Duan, T. Eiwegger, H. Grasemann, K. HayGlass, R.G. Hegele, D.L. Holness, P. Hystad, M. Kobor, T.R. Kollmann, A.L. Kozyrskyj, C. Laprise, W.Y.W. Lou, J. Macri, P.J. Mandhane, G. Miller, T.J. Moraes, P. Paré, C. Ramsey, F. Ratjen, A. Sandford, J.A. Scott, J. Scott, M.R. Sears, F. Silverman, E. Simons, T. Takaro, S. Tebbutt, T. To
Journal: Journal of Allergy and Clinical Immunology (2017)
Abstract 17987: Therapeutic Effects of Targeted PPARγ Activation on Inflamed High-Risk Plaques Assessed by Serial Optical Imaging in vivo
Authors: Jah Yeon Choi, Jiheun Ryu, Hyun Jung Kim, Joon Woo Song, Dae-Hee Lee, Dong Joo Oh, Dae-Gab Gweon, Wang-Yuhl Oh, Hongki Yoo, Kyeongsoon Park, Jin Won Kim
Journal: Circulation (2017)

Background:  Atherosclerotic plaque is a chronic inflammatory disorder with lipid accumulation within arterial walls. In particular, macrophages mediated plaque progression and rupture. While PPARγ agonist is known to have favorable pleiotropic effects on atherogenesis, its clinical application has been limited due to undesirable systemic effects.   Hypothesis:  We hypothesized that macrophage mannose receptor (MMR)-targeted nanocarrier loaded with lobeglitazone could 1) activates PPARγ pathway within plaque specifically and 2) reduce plaque burden and inflammation.   Method and Results:  We newly developed macrophage mannose receptor (MMR)-targeted biocompatible nanocarrier loaded with lobeglitazone (MMR-Lobe), which is able to specifically activate PPARγ pathways within the inflamed high-risk plaques. MMR-Lobe had a high affinity to macrophage foam cells, and it could efficiently promote cholesterol efflux via LXRα-, ABCA1, ABCG1 dependent pathway, and inhibit plaque protease expression. Using in vivo serial optical imaging of carotid artery, MMR-Lobe markedly reduced both plaque burden and inflammation in atherogenic mice without undesirable systemic effects  (Figure) . Immunofluorescence analysis from the plaque, co-activation of PPARγ, LXRα, ABCA1, and ABCG1 were strongly enhanced by MMR-Lobe treatment, whereas the expression of MMP-9 decreased significantly in the MMR-Lobe mice as compared to those in lobeglitazone per se group or controls. Comprehensive analysis of en face aorta by ex vivo imaging and immunostainings well corroborated the in vivo findings.   Conclusion:  This novel targetable PPARγ activation in macrophages could be a promising therapeutic strategy for high-risk plaques.